Piramal Pharma growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−3.1%+12.0%+15.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−36.2%+20.8%+90.4%
−85.6%+37.9%+1,040.5%
−457.7%+411.4%+109.6%
−456.5%+392.9%+108.9%
+14.6%+2.4%+5.4%
+0.5%+2.7%+16.8%
+85.2%−11.2%+107.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PPLPHARMA₹230.78

Piramal Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEGLANDWOCKPHARMAASTERDMCOHANCELALPATHLABNATCOPHARMMcap ₹30,628 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+15.4+12.0-3.1—
EBITDA Growth—+90.4+20.8-36.2—
EBIT Growth—+1,040.5+37.9-85.6—
Net Income Growth—+109.6+411.4-457.7—
EPS Growth—+108.9+392.9-456.5—
Total Assets Growth—+5.4+2.4+14.6—
Total Equity Growth—+16.8+2.7+0.5—
Cash from Operations Growth—+107.6-11.2+85.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.